Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression, and for depressive symptoms in adults with major depressive disorder with acute suicidal thoughts or behavior. WIP-DC and WIP-Rockville are both certified Spravato treatment centers, with every session given in the office under psychiatrist-led supervision.
For many patients, Spravato is the first interventional step after several antidepressants haven’t helped, and because it is often covered by insurance, it can be the most accessible one.
Prefer to text? (202) 875-6656 · weekdays
Spravato may be a good fit if:
If you’re unsure whether Spravato is right for you, a complimentary consultation is the best way to explore your options, including IV ketamine, TMS, and other approaches.
Spravato contains esketamine, a form of ketamine. Unlike traditional antidepressants, which act on serotonin and related systems and can take weeks to help, esketamine acts on the brain’s glutamate system through NMDA receptors, and for some patients it improves depressive symptoms quickly.
Spravato can be used on its own or together with an oral antidepressant; in January 2025 the FDA approved it as a standalone treatment for treatment-resistant depression. You self-administer each dose in the office, then stay for at least two hours of monitoring.
Cost and insurance: See all prices, in-network coverage, and out-of-network reimbursement on our Insurance & Fees page.
After each session, you stay in the clinic for observation and recovery under medical supervision. Vital signs, including blood pressure, are monitored and managed as needed, and discharge timing is based on your recovery.
You can’t drive after a session until the next day, so arrange a ride home in advance with a family member, friend, or car service.
Spravato within psychiatric care: your WIP psychiatrist directs the course and can combine Spravato with medication management, therapy, or TMS when depression occurs alongside anxiety, PTSD, or OCD. See how we treat co-occurring conditions.
Spravato with Dr. Navin Reddy at WIP-DC is in-network with UnitedHealthcare and Cigna, and Spravato is often covered by other commercial plans. Our staff handle the prior authorization and explain expected costs before you begin.
Spravato is esketamine, given as a nasal spray and FDA-approved for treatment-resistant depression, which is why it is often covered by insurance. IV ketamine is given by infusion and used off-label. Your psychiatrist can help you compare them.
Treatment usually starts with eight sessions over four weeks, then moves to weekly and eventually weekly or every-other-week maintenance, depending on your response.
No. You can’t drive until the next day after a session, so plan for a ride home.
Not necessarily. Spravato can be used with an oral antidepressant or on its own. Your psychiatrist will review your medications.
At WIP-DC, 4325 49th Street NW, Suite 200, Washington, DC 20016, and WIP-Rockville, 1801 Rockville Pike, Suite 110, Rockville, MD 20852.
Spravato is FDA-approved, together with an oral antidepressant, to treat depressive symptoms in adults with major depression who have acute suicidal thoughts or behavior. Its label notes it has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when needed. Learn more about rapid-acting treatment for depression with suicidal thoughts.
Call or text 988, call 911, or go to the nearest emergency room. WIP-DC and WIP-Rockville are outpatient practices and do not provide emergency care.
A complimentary, psychiatrist-led consultation reviews eligibility, insurance, and treatment planning. Call (202) 525-5123 for WIP-DC or (240) 995-6005 for WIP-Rockville.